Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
Type:
Grant
Filed:
October 19, 2021
Date of Patent:
May 10, 2022
Assignee:
Allergan, Inc.
Inventors:
Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
Abstract: The present invention relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as tools or as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), including FPR1 and FPR2, or as selective agonists of the FPR1 receptor.
Type:
Grant
Filed:
March 28, 2017
Date of Patent:
March 29, 2022
Assignee:
Allergan, Inc.
Inventors:
Tien T. Duong, Richard L. Beard, Michael E. Garst
Abstract: Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia.
Type:
Grant
Filed:
February 14, 2020
Date of Patent:
March 29, 2022
Assignee:
ALLERGAN, INC.
Inventors:
Michael R. Robinson, Mohammed Dibas, Jaya Giyanani, Anuradha Gore, Sungwook Lee, Haixia Liu, Aileen Morgan, Jihao Zhou
Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
Type:
Grant
Filed:
December 17, 2020
Date of Patent:
March 1, 2022
Assignee:
Allergan, Inc.
Inventors:
Ester Fernandez-Salas, Joanne Wang, Patton E. Garay, Lina Wong, D. Diane Hodges, Kei Roger Aoki
Abstract: Single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site; a translocation domain; a first spacer located between the non-cytotoxic protease and the protease cleavage site; and a second spacer located between the galanin targeting moiety and the translocation domain.
Type:
Grant
Filed:
May 20, 2019
Date of Patent:
February 15, 2022
Assignees:
Ipsen Bioinnovation Limited, Allergan, Inc.
Inventors:
Peter James, Keith Foster, John Chaddock, Roger Aoki, Lance Steward, Joseph Francis
Abstract: Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula: The compounds are useful for treating inflammatory and autoimmune diseases.
Type:
Grant
Filed:
August 14, 2018
Date of Patent:
December 28, 2021
Assignee:
ALLERGAN, INC.
Inventors:
Christopher D. Hein, Tien T. Duong, Santosh Sinha, Ling Li, Jeremiah H. Nguyen, David W. Old, Robert Burk, Veena Viswanath, Sandhya Rao, John E. Donello
Abstract: The present specification discloses porogen compositions comprising a core material and shell material, methods of making such porogen compositions, methods of forming such porous materials using such porogen compositions, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices.
Type:
Grant
Filed:
April 16, 2020
Date of Patent:
December 21, 2021
Assignee:
Allergan, Inc.
Inventors:
Futian Liu, Nicholas J Manesis, Xiaojie Yu, Athene W. Chan
Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
Type:
Grant
Filed:
June 7, 2021
Date of Patent:
December 21, 2021
Assignee:
Allergan, Inc.
Inventors:
Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
Abstract: Skin can be treated by piercing skin with a plurality of needles of an injection device and ejecting a dose of fluid therethrough. The device can include a housing, a plunger disposed in the housing, a cartridge disposed in the housing, and one or more dosing chambers. The plurality of needles can be coupled to the housing and be in fluid communication with the cartridge. Advancement of the plunger can cause a dose of fluid to be ejected from the plurality of needles.
Abstract: A tissue expansion device can be implanted temporarily beneath skin of a patient and removed upon predetermined expansion of overlying tissue. The device can include an expandable shell having a smooth or glossy outer surface and an injection port. The expandable shell can form an expandable chamber and have an anterior portion and a posterior portion. The injection port can be coupled to the anterior portion of the shell and be in fluid communication with the chamber and configured to permit injection of fluid into the chamber from a hypodermic needle. The device can have a plurality of tabs coupled to the posterior portion of the shell having one or more colors or attributes. The device can also include an orientation indicator visible along the anterior portion of the shell for assisting a clinician and orienting the device during the implantation procedure.
Type:
Grant
Filed:
September 13, 2019
Date of Patent:
November 2, 2021
Assignee:
Allergan, Inc.
Inventors:
David J. Schuessler, Alberto J. Flores, Daniela Rodriguez, Luis M. Solano
Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
Abstract: An implantable device used in a gastric band system includes an access port, a tube coupled to the access port, and a shielding device covering a portion of the tube. The shielding device is positioned adjacent to the access port and covers the end of the tube coupled to the access port. The shielding device is made from a puncture resistant material, to protect the tube from puncture by a misplaced syringe needle inserted by a physician.
Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
Type:
Grant
Filed:
November 4, 2019
Date of Patent:
September 21, 2021
Assignee:
Allergan, Inc.
Inventors:
Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
Abstract: The present disclosure relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as modulators of the N-formyl peptide receptor (FPR), including FPR1 and FPR2, or as selective agonists of the FPR1 receptor.
Type:
Grant
Filed:
March 28, 2017
Date of Patent:
September 14, 2021
Assignee:
ALLERGAN, INC.
Inventors:
Tien T. Duong, Richard L. Beard, Michael E. Garst
Abstract: Disclosed are antiseptic compositions for disinfecting tissues, in particular for ocular use. Methods and compositions disclosed herein include sodium chlorite, optionally in combination with a surfactant.
Type:
Grant
Filed:
April 25, 2019
Date of Patent:
August 24, 2021
Assignee:
Allergan, Inc.
Inventors:
James A. Burke, Richard S. Graham, Corine Ghosn, Alexandra Almazan, Michael Engles, Lakshmi Rajagopalan
Abstract: Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include Bulbine frutescens, Centella asiatica and a phenol derived from olives, such as oleuropein. The composition may be used in the treatment of scars formed during surgery. The composition may also be used cosmeceutically in the treatment of aged skin, and may include phosphatidylserine, vitamins, and other beneficial anti-aging ingredients.
Abstract: The present disclosure generally relates to methods of preparing spherical salt particles for industrial, medical, and other uses. The methods can include combining the angular salt particles with a quantity of finishing media, for example, into a receptacle. Thereafter, the angular salt particles and the finishing media can be moved or agitated until the angular salt particles have a desired sphericity.
Type:
Grant
Filed:
October 9, 2018
Date of Patent:
August 3, 2021
Assignee:
Allergan, Inc.
Inventors:
David J. Schuessler, Alberto J. Flores-Pujol
Abstract: The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.